CAS NO: | 1256589-74-8 |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally availableALKinhibitor with anIC50of 1.9 nM and aKdvalue of 2.4 nM (in an ATP-competitive manner), and also inhibitsALK F1174LandALK R1275QwithIC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2]. | ||||||||||||||||
IC50& Target | IC50: 1.9 nM (ALK), 1 nM (ALKF1174L), 3.5 nM (ALKR1275Q)[1] | ||||||||||||||||
体外研究 (In Vitro) | Alectinib (0-1000 nM; 2 hours; NCI-H2228 cells) treatment could prevent autophosphorylation of ALK in NCI-H2228 cells expressing EML4-ALK, and it also resulted in substantial suppression of phosphorylation of STAT3 and AKT[1]. Western Blot Analysis[1]
Cell Viability Assay[1]
| ||||||||||||||||
体内研究 (In Vivo) | Alectinib (0.2-20 mg/kg; oral administration; once daily; for 11 days; SCID or nude mice bearing NCI-H2228 cells) treatment can result in dose-dependent tumor growth inhibition (EC50of 0.46 mg/kg) and tumor regression. At any dose level, no differences in body weight or gross signs of toxicity are observed[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 519.08 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C30H35ClN4O2 | ||||||||||||||||
CAS 号 | 1256589-74-8 | ||||||||||||||||
中文名称 | 艾乐替尼盐酸盐;盐酸阿雷替尼 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 5 mg/mL(9.63 mM;Need ultrasonic) H2O :< 0.1 mg/mL(insoluble) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |